ESSA Pharma, a pharmaceutical company, which focuses on the development of small molecule drugs for the treatment of prostate cancer, agreed to acquire Realm Therapeutics, a biopharmaceutical company, for $21m. "We are very pleased to enter into this transaction with ESSA, whose lead program is a first-in-class therapy for the treatment of castration-resistant prostate cancer, which represents a significant unmet need for patients. Following a comprehensive review of strategic alternatives, Realm's Board of Directors concluded that the proposed acquisition will provide an opportunity to create meaningful value and, as such we have significant support from our shareholders for the transaction," Alex Martin, Realm Chief Executive Officer.